Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REPLIGEN DROPS HIV VACCINE PROGRAM AS PART OF STREAMLINING

Executive Summary

REPLIGEN DROPS HIV VACCINE PROGRAM AS PART OF STREAMLINING announced July 19. Repligen's RP400c therapeutic HIV vaccine targeting the V3 loop of the virus was in Phase I studies at the University of Colorado, and the company was also involved in research for a prophylactic vaccine. Both programs have been dropped because of "a lack of available funding and the exponentially increasing expenses associated with the clinical development of an HIV vaccine," Repligen said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024818

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel